小剂量卡培他滨单药治疗高龄恶性肿瘤患者的疗效和安全性

目的：观察小剂量卡培他滨单药治疗高龄恶性肿瘤患者的疗效和不良反应。方法：67例高龄（75—84岁，中位年龄79岁）初治恶性肿瘤患者（结直肠癌15例，胃癌13例，喉癌9例，口腔癌8例，卵巢癌9例，胰腺癌8例，肝细胞癌5例），每次给予卡培他滨700mg/m^2，每天2次，连用14天，休息1周，每21天重复，直到疾病进展为止。结果：PR8例（结肠癌2例，胃癌3例，喉癌1例，卵巢癌1例，胰腺癌1例），SD42例，PD17例，总有效率（ORR）11.9％，肿瘤控制率（DCR）74.6％，中位肿瘤进展时间（mTTP）5.9个月，中位生存期（mS）9.2个月。不良反应有手-足综合征发生率90％，均为Ⅰ—Ⅱ度，Ⅰ度，Ⅱ度粒细胞减少9.0％，恶心7.5％，Ⅰ度腹泻10.4％。结论：小剂量卡培他滨单药治疗高龄恶性肿瘤患者有较高肿瘤控制率，不良反应轻微。

Efficacy and safely of low -dose capecitabine monotherapy in elderly patients with malignant tumors

Objective：To observe the efficacy and side effects of low - dose capecitabine lnonotherapy in elderly patients with malignant tmnors. Methods：Sixty - seven elderly patients（froln 75 to 84 years old, median age 79 years old） with malignant tumors （15 cases of eoloreetal cancer, 13 cases of gastric carcinoma,9 cases of laryngoeareinoma, 8 cases of mouth cancer,9 cases of ovarian cancer,8 cases of pancreatic cancer,5 cases of hepatocellular cancer）were initial treated, capecitabine 700mg/m^2, oral, bid, on d1-14,then had a week rest, repeated every 21 days, until the disease progress. Results：There were 8 patients achieved partial response（PR） （2 cases of colorectal cancer,3 cases of gastric carcinoma,1 case of laryngocarcinoma,1 ease of ovarian cancer, 1 case of pancreatic cancer） ,42 patients achieved a stable disease （SD） , 17 patients were progress disease （PD）, overall response rate （ ORR ） was 11.9 % and the disease control rate（DCR） was 74.6% ,the median time to progression（mTTP） was 5.9 months and the median survival （mS） was 9.2 months. The adverse effects were grade Ⅰ/Ⅱ hand-foot syndrome （9.0%） ,grade Ⅰ/Ⅱ granuloeytopenia（9.0% ） ,nausea（7.5% ） and grade Ⅰ diarrhea（10.4% ）. Conclusion：There was a higher DCR and rain side effects in elderly patients with malignant tmnors treated by low - dose capecitabine.